[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prurigo-nodularis-pn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prurigo-nodularis-pn":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100639479","phase-2-efficacy-and-speed-of-response-of-lebrikizumab-in-high-burden-prurigo-nodularis-patients-100639479",false,"NCT07620561","Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients","Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study","Inclusion Criteria:\n\n* Age 18-80\n* Diagnosis of Prurigo Nodularis (PN) for at least 1 year\n* Active PN with moderate-to-severe itch, several nodules, and presence of nodules in more than one part of the body\n* Women of childbearing potential must agree to remain abstinent or use a highly effective contraceptive method during treatment and for at least 18 weeks after the last dose of study drug\n* Male participants must agree to use an effective barrier contraceptive if sexually active with a woman of childbearing potential during treatment and for at least 18 weeks after the last dose of study drug\n\nExclusion Criteria:\n\n* Prior participation in a lebrikizumab study\n* History of anaphylaxis\n* History of or active HIV\n* Active hepatitis or known liver cirrhosis\n* History of cancer in the past 5 years, except for fully treated early cervical cancer in situ or non-melanoma skin cancers (basal cell or squamous cell skin cancer) that have been successfully treated and resolved. This includes certain skin lymphomas such as mycosis fungoides.\n* Uncontrolled chronic conditions that may require intermittent oral steroid use, such as severe uncontrolled asthma\n* Current or recent parasitic infection\n* Immunocompromised individuals\n* Pregnant or breastfeeding women or those planning to become pregnant or breastfeed during the study period\n* Use of other treatments for PN during the study, such as topical, systemic, or light-based treatments\n* Current or recent treatment with biologic drugs\n* Use of drugs that have an effect on the immune system during the study and within 4 weeks of starting the study\n* Receipt of phototherapy or light-based therapy within 4 weeks before starting the study\n* Regular use of tanning booths or parlors within 4 weeks before starting the study\n* Receipt of a live vaccine within 12 weeks before starting the study or planned receipt during the study\n* Recent use of an experimental drug\n\nOther protocol-defined Inclusion\u002FExclusion Criteria apply.","ALL","18 Years","80 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).",[27],"Prurigo Nodularis (PN)",[29,30,31,32,33,34,35,36],"prurigo nodularis","prurigo","lebrikizumab","ebglyss","itch","pruritus","dermatitis","skin diseases","NOT_YET_RECRUITING","2026-05-26",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":21},"2026-06",{"date":45,"type":21},"2028-03",{"name":47,"class":48},"University of Maryland, Baltimore","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100611093","phase-2-study-of-the-efficacy-and-safety-of-icp-332-in-participants-with-prurigo-nodularis-100611093","NCT07236099","Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis","Inclusion Criteria :\n\n1. Voluntarily sign informed consent forms before any investigational procedure(s) are performed.\n2. Male or female aged between 18 and 75 years at the time of signing the informed consent.\n3. Clinical diagnosis of PN by a dermatologist for at least 3 months before the Screening visit.\n4. At least 20 pruriginous lesions on the entire body with a bilateral distribution (on both legs, and\u002For both arms and\u002For trunk) at both screening and the baseline (Day 1) visits.\n5. PP NRS score ≥ 7 at both screening and the baseline (Day 1) visits.\n6. IGA-CPG-S score ≥ 3 at both the screening and the baseline (Day 1) visits.\n7. History of inadequate response to topical corticosteroid of medium or higher potency or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks).\n\nWillingness to avoid pregnancy or fathering children\n\nExclusion Criteria:\n\n1. Patients with a documented AD severity moderate to severe presence of skin morbidities other than PN and mild AD that may interfere with the assessment of the study outcomes. PN secondary to medications .\n2. Any uncontrolled or serious disease, or any medical, psychological, or surgical condition including relevant laboratory abnormalities at screening that may either interfere with the interpretation of the clinical trial results and\u002For, in the investigator's judgment, would adversely affect the patient's participation in the study. Active chronic or acute infection participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.","75 Years",{"count":59,"type":21},135,[24],"Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)",[27],"RECRUITING","2026-04-08",{"date":66,"type":41},"2026-04-09",{"date":68,"type":41},"2025-11-27",{"date":70,"type":21},"2027-10",{"name":72,"class":73},"Beijing InnoCare Pharma Tech Co., Ltd.","INDUSTRY",16,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":49},"100614194","early-and-long-term-efficacy-and-immune-changes-with-dupilumab-in-prurigo-nodularis-100614194","NCT07276425","Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis","Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients","Inclusion Criteria:\n\n* Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment\n\nExclusion Criteria:\n\n* Unwilling to participate in the BioDay registry\n* (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank",{"count":83,"type":21},40,"52 Weeks","OBSERVATIONAL","With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.",[27],[29,89],"dupilumab","2025-12-11",{"date":92,"type":41},"2025-12-18",{"date":94,"type":41},"2025-06-01",{"date":96,"type":21},"2028-06-01",{"name":98,"class":48},"UMC Utrecht"]